CHRS vs. MLEC

Last updated Jun 5, 2026

CHRS (Coherus BioSciences, Inc.) and MLEC (Moolec Science SA Ordinary Shares) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, CHRS returned -31.87%/yr vs -74.00%/yr for MLEC. At a correlation of -0.02, they often move in opposite directions.

Performance

CHRS vs. MLEC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and Moolec Science SA Ordinary Shares (MLEC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CHRS achieves a 10.92% return, which is significantly lower than MLEC's 110.53% return.

CHRS

• 1D: 7.14%
• 1M: -12.01%
• YTD: 10.92%
• 6M: 28.05%
• 1Y: 97.62%
• 3Y*: -31.87%
• 5Y*: -34.70%
• 10Y*: -21.54%

MLEC

• 1D: -0.74%
• 1M: -15.63%
• YTD: 110.53%
• 6M: 8.94%
• 1Y: -92.91%
• 3Y*: -74.00%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CHRS vs. MLEC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
CHRS Coherus BioSciences, Inc.	10.92%	2.90%	-58.56%	-60.87%
MLEC Moolec Science SA Ordinary Shares	110.53%	-96.82%	-67.48%	-72.97%

Correlation

The correlation between CHRS and MLEC is -0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.09
Correlation (3Y) Calculated over the trailing 3-year period	-0.01
Correlation (All Time) Calculated using the full available price history since Jan 4, 2023	-0.02

Fundamentals

Total Revenue (TTM) CHRS : $46.88M MLEC : $7.83M
Gross Profit (TTM) CHRS : $23.41M MLEC : -$639.50K
EBITDA (TTM) CHRS : -$162.15M MLEC : -$5.21M

Return for Risk

CHRS vs. MLEC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHRS

CHRS Risk / Return Rank: 74
CHRS Sharpe Ratio Rank: 76
CHRS Sortino Ratio Rank: 74
CHRS Omega Ratio Rank: 71
CHRS Calmar Ratio Rank: 78
CHRS Martin Ratio Rank: 73

MLEC

MLEC Risk / Return Rank: 14
MLEC Sharpe Ratio Rank: 22
MLEC Sortino Ratio Rank: 12
MLEC Omega Ratio Rank: 14
MLEC Calmar Ratio Rank: 3
MLEC Martin Ratio Rank: 18

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHRS vs. MLEC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and Moolec Science SA Ordinary Shares (MLEC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CHRS	MLEC	Difference
Sharpe ratio: Return per unit of total volatility	1.21	-0.45	+1.65
Sortino ratio: Return per unit of downside risk	1.95	-0.93	+2.88
Omega ratio: Gain probability vs. loss probability	1.23	0.90	+0.34
Calmar ratio: Return relative to maximum drawdown	2.37	-0.96	+3.33
Martin ratio: Return relative to average drawdown	4.36	-1.11	+5.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CHRS vs. MLEC - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 1.21, which is higher than the MLEC Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of CHRS and MLEC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CHRS	MLEC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.21	-0.45	+1.65
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.41	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.22	-0.39	+0.17

Drawdowns

CHRS vs. MLEC - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, roughly equal to the maximum MLEC drawdown of -99.88%. Use the drawdown chart below to compare losses from any high point for CHRS and MLEC.

Drawdown Indicators

	CHRS	MLEC	Difference
Max Drawdown Largest peak-to-trough decline	-98.21%	-99.88%	+1.67%
Max Drawdown (1Y) Largest decline over 1 year	-41.43%	-97.14%	+55.71%
Max Drawdown (3Y) Largest decline over 3 years	-87.71%	-99.41%	+11.70%
Max Drawdown (5Y) Largest decline over 5 years	-96.47%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-97.88%	—	—
Current Drawdown Current decline from peak	-95.80%	-99.72%	+3.92%
Average Drawdown Average peak-to-trough decline	-63.50%	-91.73%	+28.23%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.49%	83.97%	-61.48%

Volatility

CHRS vs. MLEC - Volatility Comparison

The current volatility for Coherus BioSciences, Inc. (CHRS) is 22.10%, while Moolec Science SA Ordinary Shares (MLEC) has a volatility of 31.29%. This indicates that CHRS experiences smaller price fluctuations and is considered to be less risky than MLEC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CHRS	MLEC	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.10%	31.29%	-9.19%
Volatility (6M) Calculated over the trailing 6-month period	59.88%	163.37%	-103.49%
Volatility (1Y) Calculated over the trailing 1-year period	81.42%	207.40%	-125.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.70%	198.14%	-113.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.92%	198.14%	-123.22%

Dividends

CHRS vs. MLEC - Dividend Comparison

Neither CHRS nor MLEC has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CHRS and MLEC in my portfolio?

CHRS and MLEC have a correlation of -0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CHRS or MLEC?

MLEC has higher volatility (31.29%) compared to CHRS (22.10%). In terms of maximum drawdown, CHRS dropped -98.21% vs MLEC's -99.88%.

Which has better risk-adjusted returns?

CHRS currently has the higher Sharpe Ratio (1.21 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.